Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Oncoimmunin Inc. is active in the Biotechnology & Pharmaceuticals technology area with a portfolio that currently shows 1 pending office action. This 1 pending office action represents the only active prosecution matter for the company. The examiner assigned to this case is VANHORN, ABIGAIL LOUISE, who is the busiest examiner for the portfolio. With 1 busiest examiner pending action, the company's immediate progress in the Biotechnology & Pharmaceuticals sector is tied to this interaction.
The portfolio's prosecution is concentrated, involving 1 distinct examiner and 1 distinct art unit. This suggests that the company's innovations are concentrated within a specific niche of the pharmaceutical industry. By operating within 1 distinct art unit, the company only needs to navigate the specific standards and timelines of that unit. The presence of 1 distinct examiner means that the company can focus its resources on a single relationship rather than managing multiple examiner styles. This 1 pending office action is the sole focus of the company's current efforts to secure its intellectual property assets.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VANHORN, ABIGAIL LOUISE | 1 | 46.8% | +22.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17812657 | TARGETED AND LOCALIZED IN VIVO DELIVERY OF OLIGONUCLEOTIDES | VANHORN, ABIGAIL LOUISE | 22d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17812657 | TARGETED AND LOCALIZED IN VIVO DELIVERY OF OLIGONUCLEOTIDES | VANHORN, ABIGAIL LOUISE | 22d overdue |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17812657 | TARGETED AND LOCALIZED IN VIVO DELIVERY OF OLIGONUCLEOTIDES | VANHORN, ABIGAIL LOUISE | 1636 | §103§112Other | Non-Final OA | 22d overdue | Pending | Jul 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial